Edatrexate, an Antifolate with Antitumor Activity: A Review

References

• Matherly LH, Fry DW, Goldman ID. Role of methotrexate polyglutaniylation and cellular energy metabolism in inhibition of methotrexate binding to dihydrofolate reductase by 5 formyl-tetrahydrofolate in Ehrlich ascites tumor cells in vitro. Cancer Res 1983; 43: 2694–2699
   PubMed Web of Science ®Google Scholar
• Matherly LH, Barlowe CK, Goldman ID. Antitolate polyglutaniylation and competitive drug displacement at dihydrofolare ree as important elenients in leucovorin rescue in LI 210 cells. Cancer Res 1986; 46: 588–593
   PubMed Web of Science ®Google Scholar
• Matherly LH, Barlowe CK, Phillips VM, Goldman ID. The effects on 4-aminoantifolates on 5-formyltetrahydrofolate metabolism in L1210 cells. A biochemical basis for the selectivity of leucovorin rescue. J Biol Chem 1987; 262: 710–717
   PubMed Web of Science ®Google Scholar
• Goldman ID. Analysis of the cytotoxic dcterniinants for niethotrexate [NSC-740]. A role for “free” intracellular drug. Cancer Chemother Rep 1975; 6: 51–52
   Google Scholar
• Goldman ID. Membrane transport considerations in high-dose niethotrexate regimens with leucovorin rescue. Cancer Treat Rep 1981; 65(6)13–17, Suppl 1
   PubMedGoogle Scholar
• Sirotnak FM. Correlates of folate analog transport. phamiacokinetic and selective antitumor action. Pharmacol Ther 1980; 8: 71–103
   Web of Science ®Google Scholar
• Sirotnak FM, Chello PL, Brockman RW. Potential for exploitation of transport bystems in anticancer drug design. Methods Cancer Res 1979; 16: 382–447
   Google Scholar
• Sirotnak FM, Chello PL, DeGraw JI, . Membrane transport and the molecular basis for selective antitumor action of folate analogs. Molecular Actions and Targets for Cancer Cheniotherapeutic Agents, A. Sartorelli, et al. Acadcinic Press, New York 1982; 349
   Google Scholar
• Chello PL, Sirotnak FM, Dorick DM, et al. Therapeutic relevance of differences in the structural specificity of the transport system for folate analogs in L1210 tumor cells arid in isolated niurinc. intestinal epithelial cells. Cancer Res 1977; 37(12)4297–4303
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, Donsbach RC. Differential cell pernieability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia. Cancer Res 1973; 33(6)1290–1294
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, Donsbach RC. Funhcr evidence for a basis of selective activity and relative responsiveness during antifrilate therapy of murine tumors. Cancer Res 1975; 35(7)1737–1744
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, Donsbach RC. Kinetic currelatea of niethotrexate transport and therapeutic responsiveness in murine tumors. Cancer Res 1976; 36(3)1151–1158
   PubMedGoogle Scholar
• Sirotnak FM, Moccio DM, Goutaa LJ, et al. Biochemical correlate of responsiveness and collateral sensitivity of some niethotrexate resistant murine tumors to the lipophilic antifolate. metoprine. Cancer Res 1982; 42(3)924–928
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, DeGraw JI. Selective antitumor action of folate analogs. Folate Antagonists as Therapeutic Agents, FM. Sirotnak. Academic Press, New York 1984; Vol 2.: 43–91
   Google Scholar
• Runiberger BG, Barrueco JR, Sirotnak FM. Differing specificities for 4-aminofolate analogs of folylpolygluiamyl synthetase from tumors and proliferating intestinal epithelium of the mouse with significance for selective antitumor action. Cancer Res 1990; 50: 4639–4643
   PubMedGoogle Scholar
• Poser KG, Sirotnak FM, Chello PL. Differential synthesis oi methotrexate polyglutamates in normal proliferative and neoplastic mouse tissue in vivo. Cancer Res 1981; 41: 4441–4446
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, DeGraw JI, Moccio DM, et al. New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharniacologic properties. Cancer Chemother Pharniacol 1984; 12: 18–25
   PubMed Web of Science ®Google Scholar
• Samuels LL, Moccio DM, Sirotnak FM. Similar differential for total polyglutaniylation and cytotoxicity among various folate analogs in human and murine tumor cells in vitro. Cancer Res 1985; 45: 1488–1495
   PubMed Web of Science ®Google Scholar
• DeGraw JI, Brown VH, Tagawa H, et al. Synthesis and antitumor activity of 10-alkyl, 10-deazaaminopterins. A convenient synthesis of 10-deazaaniinoplerin. J Med Chem 1982; 25: 1227–1230
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, DeGraw JI, Moccio DM, et al. Antitumor properties of a new folate analog. 10-deazaaminopterin, in mice. Cancer Treat Rep 1978; 62: 1047–52
   PubMedGoogle Scholar
• Sirotnak FM, DeGraw JI, Chello PL. Biochemical and pharmacologic properties of a new folate analog. 10-deazaaminopterin, in mice. Cancer Treat Rep 1982; 66: 351–358
   PubMedGoogle Scholar
• Sirotnah FM, DeGraw JI, Schmid FA, et al. New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antituinor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother Pharmacol 1984; 12: 26–30
   PubMed Web of Science ®Google Scholar
• Schinid FA, Sirotnak FM, Otter GM, et al. New folate analogs of the 10-deaza-aminopterin series: Markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Cancer Treat Rep 1985; 69: 551–553
   PubMedGoogle Scholar
• Sirotnah FM, Schmid FA, Samuels LL, et al. 10-Ethyl-10-deazaaininopterin: Structural design and biochemical. pharmacologic. and antitumor properties. NCI Monogr 1987; 5: 127–131
   PubMedGoogle Scholar
• Kisliuk RL. Pterolypolyglutamates. Mol Cell Biochem 1981; 39: 131–346
   Google Scholar
• Moccio DM, Sirotnak FM, Samuels LL, et al. Similar specificity of membrane transport for folate analogues and their metabolites by murine and human tumor cells: a clinically directed laboratory study. Cancer Res 1985; 44: 3992–4000
   Google Scholar
• Kinahan JJ, Saniuels LL, Farag F, et al. Fluorimetric HPLC analysih (it 10-deaza-aniinopterin. 10-ethyl-10-deaza-aminopterin and known metabolites. Anal Biochem 1985; 150: 203–213
   PubMedGoogle Scholar
• Fanucchi MP, Kinahan JJ, Samuels LL, et al. Toxicity. elimination, and metabolism of 10-ethyl-10-deazaaminopterin in rats and dogs. Cancer Res 1987; 47: 2334–2339
   PubMed Web of Science ®Google Scholar
• Sirotnak FM. Obligate genetic expression in tumor cells of a fetal membrane property mediating “folate” transport: biological significance and implications for improved therapy ofhuman cancer. Cancer Res 1985; 45: 3992–4000
   PubMed Web of Science ®Google Scholar
• Braakhuis BJM, van Dongen GAMS, Bagnay M, et al. Preclinical chemotherapy on human head and neck cancer xenografts grown in athyniic nude mice. Head Neck 1989; 11: 511–515
   PubMed Web of Science ®Google Scholar
• Brown DH, Braakhuis BJM, van Dongen GAMS, et al. Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against human bead and neck cancer xenografts. Anticancer Res 1989; 9: 1549–1552
   PubMed Web of Science ®Google Scholar
• Schmid FA, Sirotnak FM, Otter GM, et al. Combination chemotherapy with a new folate analog: Activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models. Cancer Treat Rep 1987; 71: 727–732
   PubMedGoogle Scholar
• Sirotnah FM, Schniid FA, DeGraw JI. Intracavitary therapy of murine ovarian cancer with cis-diamminedichloroplatinum (II) and 10-ethyl-10-deazaaminopterin incorporating systemic leucovorin protection. Cancer Res 1989; 49: 2890–2893
   PubMed Web of Science ®Google Scholar
• Kris MG, Kinahan JJ, Gralla RJ, et al. Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. Cancer Res 1988; 48: 5573–5579
   PubMed Web of Science ®Google Scholar
• Tan C, Meyers P, Steinherz P, et al. Phase I clinical and pharmacologic study of 10-ethyl-10-deaza-aminopterin (10-EDAM) in children with advanced cancer. Proc Am Assoc Cancer Res 1988; 29: 230, abstract
   Web of Science ®Google Scholar
• Shum KY, Kris MG, Cralla RJ, et al. Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage Ill and IV non-small cell lung cancer. J Clin Oncol 1988; 6: 446–450
   PubMed Web of Science ®Google Scholar
• Lee JS, Libshitz HI, Murphy WK, et al. Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM: CGP 30 694) for stage IIIB or IV non-small cell lung cancer. Invest New Drugs 1990; 8: 299–304
   PubMed Web of Science ®Google Scholar
• Souhami R, Hartley J, Allen R, Rudd R, Harper P, Spiro S. 10-EdAM (10-ethyl-10-deazaaminopterin in untreated advanced non small cell lung cancer (NSCLC). Lung Cancer 1991; 7: A500, abstract
   Google Scholar
• Kemeny N, Israel K., O'Hehir M. Phase II trial of 10-Edam in patients with advanced colorcctal carcinoma. Am J Clin Oncol 1990; 13: 42–44
   PubMed Web of Science ®Google Scholar
• Schornagel JH, Cappelaere P, Cognetti F, et al. A randomizwed phase II trial of 10-ethyl-10-deaza-aminopterin and methotrexate in advanced head and neck squamous cell canccr (AHNC). an EORTC study. Proc Am Soc Clin Oncol 1989; 8: 174, abstract
   Google Scholar
• Kris MG, Gralla RJ, Potanovich LM, et al. Assessnicnt of pretreatment symptoms and improvement after edam + mitoniycin + vinblastine (EMV) in patients (pts) with inopcrahle non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1990; 9: 229, abstract
   Google Scholar
• Kris MG, Gralla RJ, Potanovich LM, Marks LD, Pistcrs KMW. Long term survival analysis of stage III and IV non-small cell lung cancer patients (pts) treated with edatrexatc (ETX. 10-Edam). Lung Cancer 1991; 7: A408, abstract
   Google Scholar
• Lee JS, Libshitz HI, Fossela FV, Murphy WK, Pang A, Lippman SM, Shin DM, Dimery IW, Glisson BS, Hong WK. Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer. Cancer 1991; 68: 959–964
   PubMed Web of Science ®Google Scholar
• Lee JS, Murphy WK, Shirinian MH, Pang A, Hong WK. Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: Potential for improved therapeutic efficacy. Cancer Cheniother Pharmacol 1991; 28: 199–204
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414–22
   PubMed Web of Science ®Google Scholar
• Vandenberg T, Pritchard KI, Eisenhauer E, et al. Phase II study of weekly 10-EDAM (Edatrexate) as first line chemotherapy for metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group Study. Proc Am Soc Clin Oncol 1992; 11: 51, abstract
   Google Scholar
• Wiesenfcld M, Su J, Jett J. Phase II study of edatrcxate (10-EdAM) in patients with small cell carcinoma of the lung. Proc Am Soc Clin Oncol 1992; 11: 311, abstract
   Google Scholar